Assessing Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Incidence of Major Adverse Cardiovascular Events: A Retrospective Cohort Study.

ABSTRACT:

Purpose

Clopidogrel, an antiplatelet agent used to prevent ischemic events, may interact with proton pump inhibitors (PPIs), especially omeprazole and esomeprazole, and reduce its effectiveness. The evidence surrounding this interaction remains controversial. This study investigates whether co-prescribing clopidogrel with PPIs is associated with a higher incidence of major adverse cardiovascular events (MACEs) compared to clopidogrel monotherapy.

Methods

We conducted a retrospective cohort study analyzing data from the Real-world Evidence Research Network in Saudi Arabia from 2016 to 2023. Patients were followed from their initial clopidogrel prescription until the occurrence of MACEs or the end of follow-up. We employed stabilized inverse probability of treatment weighting

SUBMITTER: Algabbani AM 

PROVIDER: S-EPMC12520052 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature